Gene Expression Profiling Identified TP53MutPIK3CAWild as a Potential Biomarker for Patients With Triple‑negative Breast Cancer Treated With Immune Checkpoint Inhibitors

Oncology Letters - Greece
doi 10.3892/ol.2020.11381
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Risk of Myocarditis in Patients With Cancer Treated With Immune Checkpoint Inhibitors

Chronicles of Oncology
2018English

Immune-Related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Anticancer Research
MedicineCancer ResearchOncology
2020English

Where Do the Immune Checkpoint Inhibitors Stand in the Management of Triple Negative Breast Cancer?

Immunotherapy
OncologyAllergyImmunology
2018English

PIM-1 Kinase: A Potential Biomarker of Triple-Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Palliative Radiotherapy in Advanced Cancer Patients Treated With Immune‑checkpoint Inhibitors: The PRACTICE Study

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2019English

Prognostic Genes of Triple‑negative Breast Cancer Identified by Weighted Gene Co‑expression Network Analysis

Oncology Letters
Cancer ResearchOncology
2019English

Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here

Cancer
Cancer ResearchOncology
2018English

Prognostic Value of ERBB4 Expression in Patients With Triple Negative Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy